Brief: Compugen's Com701 In Combination Demonstrates Preliminary Anti-Tumor Activity In Ovarian Cancer Patients
01/12/2022 12:19
Dec 1 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN'S COM701 (ANTI-PVRIG) IN DUAL AND TRIPLE
COMBINATION
DEMONSTRATES PRELIMINARY ANTI-TUMOR ACTIVITY AND IMMUNE
ACTIVATION IN PLATINUM RESISTANT OVARIAN CANCER PATIENTS
Source text for Eikon: ID:nPn4VGpS5a
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025